AstraZeneca PLC (AZN )

Currency in USD Disclaimer

$71.46 +$1.58 (2.26%)

Closed 07/01/2025

Day's Range

$70.04

$72.01

52 wk Range

$61.24

$87.68

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Symbol AZN
Company AstraZeneca PLC
Price $71.46
Changes Percentage 2.26
Change 1.58
Day Low $70.04
Day High $72.01
Year High $87.68
Year Low $61.24
Market Cap $432,075,935,949
Price Avg 50 EMA (D) $70.38
Price Avg 200 EMA (D) $71.48
Exchange NASDAQ
Volume 4,023,184
Average Volume 5,319,953
Open $70.09
Previous Close $69.88
EPS 2.48
PE 28.10
Earnings Announcement 2025-07-29 06:00:00
Shares Outstanding $6,200,860,160

Company brief: ASTRAZENECA PLC (AZN )

Sector Healthcare
Industry Drug Manufacturers - General
CEO Mr. Pascal Soriot D.V.M., M.B.A.
Website https://www.astrazeneca.com
Headquarters GB
Employees (FY) N/A
Founded 05-12-1993
ISIN US0463531089

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.